Trial · NCT03290781
Results by group127
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 127
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Remission Based on Composite Score at Week 52 | ONTA 25 mg/ Placebo | 6 | Participants | ||
| Number of Participants With Remission Based on Composite Score at Week 52 | ONTA 25 mg/ONTA 25 mg | 38 | Participants | ||
| Number of Participants With Remission Based on Composite Score at Week 52 | ONTA 75 mg/Placebo | 11 | Participants | ||
| Number of Participants With Remission Based on Composite Score at Week 52 | ONTA 75 mg/ONTA 75 mg | 33 | Participants | ||
| Number of Participants With Endoscopic Remission at Week 52 | ONTA 25mg/Placebo | 7 | Participants | ||
| Number of Participants With Endoscopic Remission at Week 52 | ONTA 25mg/ONTA 25mg | 40 | Participants | ||
| Number of Participants With Endoscopic Remission at Week 52 | ONTA 75mg/Placebo | 13 | Participants | ||
| Number of Participants With Endoscopic Remission at Week 52 | ONTA 75mg/ONTA 75mg | 40 | Participants | ||
| Number of Participants With Clinical Remission at Week 52 | ONTA 25mg/Placebo | 13 | Participants | ||
| Number of Participants With Clinical Remission at Week 52 | ONTA 25mg/ONTA 25mg | 48 | Participants | ||
| Number of Participants With Clinical Remission at Week 52 | ONTA 75mg/Placebo | 19 | Participants | ||
| Number of Participants With Clinical Remission at Week 52 | ONTA 75mg/ONTA 75mg | 42 | Participants | ||
| Number of Participants With Sustained Remission at Week 52 | ONTA 25mg/Placebo | 4 | Participants | ||
| Number of Participants With Sustained Remission at Week 52 | ONTA 25mg/ONTA 25mg | 23 | Participants | ||
| Number of Participants With Sustained Remission at Week 52 | ONTA 75mg/Placebo | 7 | Participants | ||
| Number of Participants With Sustained Remission at Week 52 | ONTA 75mg/ONTA 75mg | 22 | Participants | ||
| Number of Participants With Clinical Response Based on Composite Score at Week 52 | ONTA 25mg/Placebo | 15 | Participants | ||
| Number of Participants With Clinical Response Based on Composite Score at Week 52 | ONTA 25mg/ONTA 25mg | 49 | Participants | ||
| Number of Participants With Clinical Response Based on Composite Score at Week 52 | ONTA 75mg/Placebo | 20 | Participants | ||
| Number of Participants With Clinical Response Based on Composite Score at Week 52 | ONTA 75mg/ONTA 75mg | 47 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03290781/results